Affiliation:
1. Department of Physics, University of Agriculture, Faisalabad, 38040 Pakistan
2. Department of Chemistry, College of Science,
King Khalid University Abha, 61413 Saudi Arabia
Abstract
Abstract:
Cancer nano-therapeutics are rapidly evolving and are often used to overcome a number of concerns
with traditional drug delivery methods, including non-specific drug targeting and distribution, low oral bioavailability,
and poor hydrophilicity. Modern nano-based targeting techniques have been developed as a result of
advances in nano vehicle engineering and materials science, which may bring people with cancer a new hope.
Clinical trials have been authorized for a number of medicinal nanocarriers. Nanocarriers with the best feasible
size and surface attributes have been developed to optimize biodistribution and increase blood circulation duration.
Nanotherapeutics can carry preloaded active medicine towards cancerous cells by preferentially leveraging
the specific physiopathology of malignancies. In contrast to passive targeting, active targeting strategies involving
antigens or ligands, developed against specific tumor sites, boost the selectivity of these curative nanovehicles.
Another barrier that nanoparticles may resolve or lessen is drug resistance. Multifunctional and complex
nanoparticles are currently being explored and are predicted to usher in a new era of nanoparticles that will
allow for more individualized and customized cancer therapy. The potential prospects and opportunities of
stimuli-triggered nanosystems in therapeutic trials are also explored in this review.
Funder
King Khalid University, Saudi Arabia
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Pharmacology
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献